Hosted on MSN9h
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
2 Stocks to Buy With Less Than $40
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, ...
Becker's Hospital Review20h
A spoonful of innovation: Karmanos pioneers at-home liver cancer treatment
TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...
The American Journal of Managed Care4d
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...
The American Journal of Managed Care15h
Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...
Cure Today3d
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...